TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19276858

Group type: EXPERIMENTAL
Intervention: 1.0 microg of 19‐norandrostenedione
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2.5 microg of 19‐norandrostenedione
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5.0 microg of 19‐norandrostenedione
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All doses of 19‐norandrostenedione
Number of subjects: 20
Study: 17531768

Group type: EXPERIMENTAL
Intervention: Nonconsensual sexual experiences reported by boys (touched against their will)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Nonconsensual sexual experiences reported by girls (touched against their will)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Factors associated with nonconsensual experiences for boys (ever worked)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Factors associated with nonconsensual experiences for girls (ever worked)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Factors associated with nonconsensual experiences for boys (friend of opposite gender)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Factors associated with nonconsensual experiences for girls (friend of opposite gender)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Reported attempted forced physical relationship for boys (ever worked)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Reported attempted forced physical relationship for boys (friend of opposite gender)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Reported attempted forced physical relationship for girls (friend of opposite gender)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Perpetrators of nonconsensual experiences for boys
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Perpetrators of nonconsensual experiences for girls
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Reported forced physical relationship for boys
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Reported forced physical relationship for girls
Number of subjects: 1057
Study: 16956333

Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open colposuspension
Number of subjects: 0
Study: 15358988

Group type: EXPERIMENTAL
Intervention: Reboxetine 4 mg/day
Number of subjects: 28
Study: 10730729

Group type: EXPERIMENTAL
Intervention: Midazolam + Alfentanil
Number of subjects: 82

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Midazolam + Propofol
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Midazolam + Alfentanil + Propofol
Number of subjects: 82
Study: 9013010

Group type: EXPERIMENTAL
Intervention: Lytic therapy followed by heparin and warfarin (group 2)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional treatment (heparin and warfarin) (group 1)
Number of subjects: 19
Study: 1334103

Group type: EXPERIMENTAL
Intervention: Conservative surgery and radiation therapy
Number of subjects: 0
Study: 3922338

Group type: EXPERIMENTAL
Intervention: Débridement alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Trifluridine (trifluorothymidine) alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Débridement combined with trifluridine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 34
Study: 31183384

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 23
Study: 28716351

Group type: EXPERIMENTAL
Intervention: Home-based curative health services provided by trained lady health workers (LHWs) including neonatal bag and mask resuscitation and oral amoxicillin for suspected infections.
Number of subjects: 499734

Group type: COMPARATOR
Intervention: Routine care through the existing national programme (Control group).
Number of subjects: 499734

Group type: EXPERIMENTAL
Intervention: Home-based curative health services provided by LHWs.
Number of subjects: 499734
Study: 25458801

Group type: EXPERIMENTAL
Intervention: Fibrocaps
Number of subjects: 719

Group type: COMPARATOR
Intervention: Gelatin sponge
Number of subjects: 719
Study: 23539641

Group type: EXPERIMENTAL
Intervention: Orvepitant 30 mg/day
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Orvepitant 60 mg/day
Number of subjects: 673

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 673
Study: 21668750

Group type: EXPERIMENTAL
Intervention: Repetitive spinal magnetic stimulation (SMS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Sham SMS)
Number of subjects: 20
Study: 19697826

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB) before induction of general anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard opioid general anaesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 60
Study: 17309383

Group type: EXPERIMENTAL
Intervention: Agaricus blazei Murill (ABM) extract 1500 mg daily for 12 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 72
Study: 15549975

Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 21079385

Group type: EXPERIMENTAL
Intervention: Bio-Hep-B
Number of subjects: 36

Group type: COMPARATOR
Intervention: Engerix-B
Number of subjects: 36
Study: 9556464

Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin every other day
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Self-selected aspirin use after 1988
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Control group (placebo) after 1988
Number of subjects: 22071
Study: 7884326

Group type: EXPERIMENTAL
Intervention: Direct Break (DB) procedures
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rotary Break (RB) procedures
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both DB and RB methods
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DB and RB procedures
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SMT procedures
Number of subjects: 18
Study: 3228680

Group type: EXPERIMENTAL
Intervention: Caffeine (7 mg.kg‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29785716

Group type: EXPERIMENTAL
Intervention: VE plus TAS
Number of subjects: 221

Group type: COMPARATOR
Intervention: VE only
Number of subjects: 221
Study: 28933873

Group type: EXPERIMENTAL
Intervention: Note-taking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Note-taking plus note-reading
Number of subjects: 0

Group type: COMPARATOR
Intervention: Note-taking plus testing
Number of subjects: 0
Study: 26311750

Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Prednisone/prednisolone (PRED)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Daily administration of DFZ
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Daily PRED
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Daily DFZ
Number of subjects: 340
Study: 23146816

Group type: EXPERIMENTAL
Intervention: Tariquidar (TQD) at 4 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tariquidar (TQD) at 6 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tariquidar (TQD) at 8 mg/kg
Number of subjects: 15
Study: 22011689

Group type: EXPERIMENTAL
Intervention: Tocilizumab 10 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tocilizumab 20 mg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 18438201

Group type: EXPERIMENTAL
Intervention: Chronic illness self-management training
Number of subjects: 415
Study: 17021768

Group type: EXPERIMENTAL
Intervention: Efalizumab (1 mg/kg once weekly)
Number of subjects: 2719

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2719

Group type: EXPERIMENTAL
Intervention: Efalizumab (in one study with n=793)
Number of subjects: 2719

Group type: COMPARATOR
Intervention: Placebo (in one study with n=793)
Number of subjects: 2719

Group type: EXPERIMENTAL
Intervention: Efalizumab (extended treatment phase)
Number of subjects: 2719

Group type: EXPERIMENTAL
Intervention: Efalizumab (long-term treatment phase)
Number of subjects: 2719
Study: 14735295

Group type: EXPERIMENTAL
Intervention: quetiapine 25 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: quetiapine 100 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 11103798

Group type: EXPERIMENTAL
Intervention: ONYX-015 (1 x 10^10 pfu via intratumoral injection for 5 days during week 1 of each 3-week cycle)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ONYX-015 (1 x 10^10 pfu twice a day for 10 days during weeks 1 and 2 of each 3-week cycle)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: p53 mutant tumors
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 37
Study: 9197929

Group type: EXPERIMENTAL
Intervention: Selenium (Se) administration at 4000 micrograms per day from 4 days before to 4 days after chemotherapy in group A.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Selenium (Se) administration in group A.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no Se administration in first cycle, Se in second cycle).
Number of subjects: 41
Study: 1347223

Group type: EXPERIMENTAL
Intervention: Desflurane and N2O
Number of subjects: 45

Group type: COMPARATOR
Intervention: Isoflurane and N2O
Number of subjects: 45
Study: 2991832

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen for 25 days each month
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 150 mg of depo‐medroxyprogesterone acetate intramuscularly every three months
Number of subjects: 35
Study: 29898645

Group type: EXPERIMENTAL
Intervention: Auricular 'battlefield' acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 0
Study: 27315367

Group type: EXPERIMENTAL
Intervention: Computer-based training system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional training only
Number of subjects: 40
Study: 24169657

Group type: EXPERIMENTAL
Intervention: DISC lens (n=111)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Single vision (SV) lens (n=110)
Number of subjects: 221
Study: 24373364

Group type: EXPERIMENTAL
Intervention: Exercise group (3 sessions/week, 2 in water, 1 on land), n=42
Number of subjects: 72
Study: 19594988

Group type: EXPERIMENTAL
Intervention: Homing in on health (HIOH) illness self-management intervention
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 384
Study: 18812733

Group type: EXPERIMENTAL
Intervention: 3% albumin solution (L group, n = 68)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 5% albumin (H group, n = 83)
Number of subjects: 151
Study: 16815748

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.125 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.50 mg
Number of subjects: 109
Study: 12823650

Group type: EXPERIMENTAL
Intervention: Enhanced care intervention
Number of subjects: 211

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 211
Study: 10972371

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice-weekly subcutaneous injections)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9117012

Group type: EXPERIMENTAL
Intervention: Prednisolone (20 mg for 2 weeks followed by 10 mg for 4 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison of treatment groups
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 27
Study: 10071548

Group type: EXPERIMENTAL
Intervention: Alfuzosin (12 months treatment)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Alfuzosin (12-18 months treatment)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 131
Study: 3728935

Group type: EXPERIMENTAL
Intervention: Intravenous fluids (2 litres)
Number of subjects: 212

Group type: COMPARATOR
Intervention: No intravenous fluids
Number of subjects: 212
Study: 31917122

Group type: EXPERIMENTAL
Intervention: SOX (100 mg/m2 of oxaliplatin on day 1 and 80 mg/m2 of S-1 on days 1-14, every 21 days, 8 cycles)
Number of subjects: 955

Group type: COMPARATOR
Intervention: UFT/LV (300 mg/m2 of UFT and 75 mg/day of LV on days 1-28, every 35 days, 5 cycles)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: SOX in N2b subgroup
Number of subjects: 955

Group type: COMPARATOR
Intervention: UFT/LV in N2b subgroup
Number of subjects: 955
Study: 29435790

Group type: EXPERIMENTAL
Intervention: Robotically controlled ablation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manually controlled ablation
Number of subjects: 50
Study: 27842269

Group type: EXPERIMENTAL
Intervention: Intensive Language‐Action Therapy (ILAT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Naming Therapy
Number of subjects: 18
Study: 24200249

Group type: EXPERIMENTAL
Intervention: Relaxation therapy (shavasana with soothing background music) daily for 1 hour for 6 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no relaxation techniques)
Number of subjects: 67
Study: 23357775

Group type: EXPERIMENTAL
Intervention: Tigecycline 100 mg (150 mg followed by 75 mg every 12 h)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Tigecycline 75 mg (200 mg followed by 100 mg every 12 h)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (1 g every 8 h)
Number of subjects: 67
Study: 20150324

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4570

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 4570
Study: 19142480

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 105
Study: 16147970

Group type: EXPERIMENTAL
Intervention: Dornase alfa after physiotherapy/PEP
Number of subjects: 52
Study: 14974909

Group type: EXPERIMENTAL
Intervention: Oral oestrogen (Premarin 1.25 mg) + Norethisterone (2.5 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + MPA (10 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Norethisterone (2.5 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral oestrogen (Premarin 1.25 mg) + MPA (10 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + CA (5 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Dydrogesterone (20 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral oestrogen (Premarin 1.25 mg) + Progestogens (various types)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Progestogens (various types)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral oestrogen (Premarin 1.25 mg) + MPA (10 mg) and Norethisterone (2.5 mg)
Number of subjects: 19
Study: 12458987

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Combination therapy (alendronate and estrogen)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Estrogen 0.625 mg/d
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 10068162

Group type: EXPERIMENTAL
Intervention: Acute pain (100 s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tonic/unilateral face pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tonic/bilateral face pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Persistent/bilateral face pain
Number of subjects: 0
Study: 7738622

Group type: EXPERIMENTAL
Intervention: 5‐FU 600 mg/m2 plus FA 300 mg/m2 on days 2 to 4 with DP 75 mg orally three times daily on days 1 to 5
Number of subjects: 181

Group type: COMPARATOR
Intervention: 5‐FU 600 mg/m2 plus FA 300 mg/m2 on days 2 to 4 without DP
Number of subjects: 181
Study: 1914056

Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% bupivacaine with epinephrine 5 micrograms.ml‐1 (bupivacaine group, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 20 ml preservative-free saline (placebo group, n = 10)
Number of subjects: 20
Study: 7267679

Group type: EXPERIMENTAL
Intervention: 25 mg LM 5008
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1 mg atropine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6428290

Group type: EXPERIMENTAL
Intervention: L-thyroxine therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 29116394

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard Protocol (SP)
Number of subjects: 27
Study: 26746371

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 8099
Study: 24720558

Group type: EXPERIMENTAL
Intervention: Supine OSA with AHIS:AHINS ratio ≥4:1 and AHINS <10 events/hour
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Supine OSA definitions
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: AHINS <10 events/hour
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Males with supine OSA
Number of subjects: 75
Study: 23535791

Group type: EXPERIMENTAL
Intervention: NEurocognitive Joyful Attentive Training Intervention (NEJATI) in 12 sessions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 20542844

Group type: EXPERIMENTAL
Intervention: ATV/RTV + ABC/3TC
Number of subjects: 515
Study: 18386544

Group type: COMPARATOR
Intervention: Single-surface intensive phototherapy (SsIPT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Double-surface intensive phototherapy (DsIPT)
Number of subjects: 60
Study: 16804654

Group type: EXPERIMENTAL
Intervention: Piperacillin (Pip) plus aminoglycoside (AMG)
Number of subjects: 717

Group type: COMPARATOR
Intervention: Third generation cephalosporin (Ceph) plus AMG
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Imipenem (Imi) plus glycopeptide (GLP)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Imi/GLP plus amphotericin B deoxycholate (AmB) plus 5-flucytosine (5-FC)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Imi/GLP plus fluconazole (Fluco)
Number of subjects: 717
Study: 14550686

Group type: EXPERIMENTAL
Intervention: IV heroin maintenance treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IV methadone maintenance treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11079510

Group type: COMPARATOR
Intervention: Noninjured cohort (C)
Number of subjects: 70
Study: 8669677

Group type: EXPERIMENTAL
Intervention: 5% hyperbaric lidocaine with epinephrine (60 mg for arthroscopy or 75 mg for hernia repair)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 2% isobaric lidocaine without epinephrine (60 mg for arthroscopy or 75 mg for hernia repair)
Number of subjects: 159

Group type: COMPARATOR
Intervention: 0.75% hyperbaric bupivacaine without epinephrine (7.5 mg for arthroscopy or 9.0 mg for hernia repair)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 5% hyperbaric lidocaine with epinephrine
Number of subjects: 159

Group type: COMPARATOR
Intervention: 0.75% hyperbaric bupivacaine
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Patients undergoing arthroscopy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Patients undergoing hernia repair
Number of subjects: 159
Study: 1303319

Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 265
Study: 3897560

Group type: EXPERIMENTAL
Intervention: 20 mg/kg Oltipraz (single dose)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 20 mg/kg Oltipraz (split dose)
Number of subjects: 151
Study: 29574445

Group type: EXPERIMENTAL
Intervention: Kiosk management
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nurse management
Number of subjects: 120
Study: 27531573

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride/acetaminophen combination (TRAM/APAP)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug (NSAID)
Number of subjects: 280
Study: 23839330

Group type: EXPERIMENTAL
Intervention: Small stitches
Number of subjects: 691

Group type: COMPARATOR
Intervention: Large stitches
Number of subjects: 691
Study: 22213771

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 279

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 279

Group type: COMPARATOR
Intervention: Divalproex sodium
Number of subjects: 279
Study: 20541573

Group type: EXPERIMENTAL
Intervention: High disinhibition
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Restrained eaters
Number of subjects: 33

Group type: COMPARATOR
Intervention: Restraint
Number of subjects: 33
Study: 18951617

Group type: EXPERIMENTAL
Intervention: Milk oral immunotherapy (OIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15688279

Group type: EXPERIMENTAL
Intervention: rgp120 vaccine
Number of subjects: 5403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5403
Study: 12549814

Group type: EXPERIMENTAL
Intervention: KP model
Number of subjects: 5499

Group type: EXPERIMENTAL
Intervention: State model
Number of subjects: 5499

Group type: COMPARATOR
Intervention: Control model
Number of subjects: 5499
Study: 11236255

Group type: EXPERIMENTAL
Intervention: Patients with LVH (35.8% in mild HT, 68.18% in moderate HT, 100% in severe HT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patients with LVH
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patients without LVH
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (39 healthy normotensives)
Number of subjects: 121
Study: 8991490

Group type: EXPERIMENTAL
Intervention: Dilacor XR (180 mg d‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilacor XR (540 mg d‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilacor XR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardizem CD
Number of subjects: 0